Literature DB >> 19582455

Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.

Sana Intidhar Labidi1, Christine Ménétrier-Caux, Sylvie Chabaud, Catherine Chassagne, Catherine Sebban, Thérèse Gargi, Pierre Biron, Jean-Yves Blay, Hervé Ghesquières.   

Abstract

The prognosis of follicular lymphoma could vary with the tumor immune microenvironment. We evaluated the prognostic value of serum levels of ten cytokines. Our study cohort included 60 follicular lymphoma patients and 20 controls. Serum was available at diagnosis in 31 patients, at first relapse in 18, and complete remission in 11. Bioplex technology was used for determination of nine cytokines [interleukin (IL)-1Ra, IL-6, IL-7, IL-10, IL-13, tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (b-FGF)]. Transforming growth factor beta (TGF-β) was measured by sandwich enzyme-linked immunosorbent assay. IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, and PDGF levels were found increased in follicular lymphoma patients compared to controls. Multivariate analysis identified early stage and high TGF-β levels as independent predictors of overall survival associated with improved outcome. High lactate dehydrogenase and VEGF levels were independently associated with poorer progression-free survival. These results show the prognostic value of TGF-β and VEGF in follicular lymphoma and suggest their contribution to tumor microenvironment alterations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582455     DOI: 10.1007/s00277-009-0777-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  17 in total

1.  IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Toshiro Niki; Mitsuomi Hirashima; Anne J Novak; Thomas E Witzig; Stephen M Ansell
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

2.  Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Michelle K Manske; Thomas E Witzig; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

3.  Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

Authors:  Bridget Charbonneau; Matthew J Maurer; Stephen M Ansell; Susan L Slager; Zachary S Fredericksen; Steven C Ziesmer; William R Macon; Thomas M Habermann; Thomas E Witzig; Brian K Link; James R Cerhan; Anne J Novak
Journal:  Cytokine       Date:  2012-09-23       Impact factor: 3.861

4.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Authors:  Muhammad A Mir; Matthew J Maurer; Steven C Ziesmer; Susan L Slager; Thomas Habermann; William R Macon; Brian K Link; Sergei Syrbu; Thomas Witzig; Jonathan W Friedberg; Oliver Press; Michael LeBlanc; James R Cerhan; Anne Novak; Stephen M Ansell
Journal:  Blood       Date:  2014-11-24       Impact factor: 22.113

Review 5.  Transforming growth factor-β: A therapeutic target for cancer.

Authors:  Sulsal Haque; John C Morris
Journal:  Hum Vaccin Immunother       Date:  2017-06-02       Impact factor: 3.452

6.  Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Authors:  Mark Kirschbaum; Paul Frankel; Leslie Popplewell; Jasmine Zain; Maria Delioukina; Vinod Pullarkat; Deron Matsuoka; Bernadette Pulone; Arnold J Rotter; Igor Espinoza-Delgado; Auayporn Nademanee; Stephen J Forman; David Gandara; Edward Newman
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.

Authors:  Yi Lin; Michael P Gustafson; Peggy A Bulur; Dennis A Gastineau; Thomas E Witzig; Allan B Dietz
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

8.  Identification of predictive pathways for non-hodgkin lymphoma prognosis.

Authors:  Xuesong Han; Yang Li; Jian Huang; Yawei Zhang; Theodore Holford; Qing Lan; Nathaniel Rothman; Tongzhang Zheng; Michael R Kosorok; Shuangge Ma
Journal:  Cancer Inform       Date:  2010-12-07

Review 9.  VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.

Authors:  Jing Yang; Wenlu Li; Xin He; Guofei Zhang; Lan Yue; Ying Chai
Journal:  Dis Markers       Date:  2015-02-25       Impact factor: 3.434

10.  PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.

Authors:  Z-Z Yang; D M Grote; S C Ziesmer; B Xiu; A J Novak; S M Ansell
Journal:  Blood Cancer J       Date:  2015-02-20       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.